Immediate Impact

58 standout
Sub-graph 1 of 23

Citing Papers

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
2024 Standout
Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities
2023 Standout
2 intermediate papers

Works of Adel Zaatar being referenced

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
2013
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study
2012

Author Peers

Author Last Decade Papers Cites
Adel Zaatar 324 368 104 124 9 467
She-Juan An 278 361 136 137 7 447
Eamon M. Berge 301 418 140 228 14 532
J. M. Sanchez 291 313 136 206 15 488
Maria K. Hristova‐Kazmierski 255 303 43 101 8 443
Jan Nyrop Jakobsen 188 278 105 146 16 455
Alessandro Gamboni 264 359 154 103 12 447
Kim-Son H. Nguyen 257 289 105 199 7 419
D. Chu 356 426 108 125 6 502
Eri Toyoshima 327 233 73 219 15 493
Takashi Nakaoku 292 374 187 242 13 562

All Works

Loading papers...

Rankless by CCL
2026